Cargando…

Vitamin-K-antagonist phenprocoumon versus low-dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: a real-world analysis of German claims data

BACKGROUND: For stroke prevention in patients with atrial fibrillation (AF), direct oral anticoagulants (DOACs) have been increasingly prescribed instead of vitamin-K-antagonists (VKA). For some patients a lower dosage of DOACs (ld-DOACs) is recommended. Ld-DOAC prescribing seems to be common, altho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Warkentin, Lisette, Hueber, Susann, Deiters, Barthold, Klohn, Florian, Kühlein, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137171/ https://www.ncbi.nlm.nih.gov/pubmed/35619140 http://dx.doi.org/10.1186/s12959-022-00389-9

Ejemplares similares

Vitamin-K-antagonist phenprocoumon versus direct oral anticoagulants in patients with atrial fibrillation: a real-world analysis of German claims data
por: Warkentin, Lisette, et al.
Publicado: (2023)

Comparison of phenprocoumon with direct oral anticoagulants in catheter ablation of atrial fibrillation
por: Gjermeni, Diona, et al.
Publicado: (2023)

Short- and medium-term cost effects of non-indicated thyroid diagnostics: empirical evidence from German claims data
por: Hafner, Lucas, et al.
Publicado: (2021)

Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic
por: Kow, Chia Siang, et al.
Publicado: (2022)

Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic
por: Kow, Chia Siang, et al.
Publicado: (2022)

Consequences of early thyroid ultrasound on subsequent tests, morbidity and costs: an explorative analysis of routine health data from German ambulatory care
por: Hueber, Susann, et al.
Publicado: (2023)

A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC
por: Blin, Patrick, et al.
Publicado: (2015)

Phenprocoumon based anticoagulation is an underestimated factor in the pathogenesis of calciphylaxis
por: Russ, Philipp, et al.
Publicado: (2019)

Uninterrupted DOACs Approach for Catheter Ablation of Atrial Fibrillation: Do DOACs Levels Matter?
por: Hardy, Michael, et al.
Publicado: (2022)

Active monitoring of adverse reactions following COVID-19 and other vaccinations: a feasibility study as part of the CoVaKo project
por: Zeschick, Nikoletta, et al.
Publicado: (2022)

Clinical outcomes in patients receiving edoxaban or phenprocoumon for prevention of stroke in atrial fibrillation: a German real-world cohort study
por: Hohmann, Christopher, et al.
Publicado: (2022)

Resolution of left atrial appendage thrombi: No difference between phenprocoumon and non‐vitamin K‐dependent oral antagonists
por: Biller, Katharina, et al.
Publicado: (2022)

Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis
por: Noviyani, Rini, et al.
Publicado: (2022)

Contemporary trends and barriers to oral anticoagulation therapy in Non-valvular atrial fibrillation during DOAC predominant era
por: Sehrawat, Ojasav, et al.
Publicado: (2023)

Direct oral anticoagulants (DOAC) versus vitamin K antagonist in left ventricular thrombus: An updated meta‐analysis
por: Shrestha, Dhan B., et al.
Publicado: (2023)

Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study
por: Warkentin, Lisette, et al.
Publicado: (2022)

Reactogenicity and safety of COVID-19 primary immunisation and booster vaccination regimens: a comparative observational cohort study
por: Warkentin, Lisette, et al.
Publicado: (2023)

Patient-reported reactogenicity and safety of COVID-19 vaccinations vs. comparator vaccinations: a comparative observational cohort study
por: Werner, Felix, et al.
Publicado: (2023)

Prescription of DOACs in Patients with Atrial Fibrillation at Different Stages of Renal Insufficiency
por: Hahn, Kai, et al.
Publicado: (2023)

Clinical outcomes in patients with atrial fibrillation treated with DOACs in a specialized anticoagulation center: Critical appraisal of real-world data
por: Moret, Carla, et al.
Publicado: (2023)

New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs)
por: van Gorp, Rick H., et al.
Publicado: (2015)

Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters
por: Geisen, Christof, et al.
Publicado: (2010)

Laboratory Monitoring of Direct Oral Anticoagulants (DOACs)
por: Dunois, Claire
Publicado: (2021)

Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
por: Undas, Anetta, et al.
Publicado: (2020)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Drug interaction: Omeprazole and Phenprocoumon
por: Enderle, Christa, et al.
Publicado: (2001)

Anticoagulant Treatment Adherence and Persistence in German Patients with Atrial Fibrillation
por: Patti, Giuseppe, et al.
Publicado: (2023)

Pharmacokinetics of Phenprocoumon in Emergency Situations–Results of the Prospective Observational RADOA-Registry (Reversal Agent Use in Patients Treated with Direct Oral Anticoagulants or Vitamin K Antagonists Registry)
por: Lindhoff-Last, Edelgard, et al.
Publicado: (2022)

Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation
por: Giugliano, Robert P
Publicado: (2022)

Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis
por: Li, Wenhao, et al.
Publicado: (2022)

Low-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
por: Lee, Ki Hong, et al.
Publicado: (2023)

New Direct Oral Anticoagulants (DOAC) and Their Use Today
por: Schwarb, Heike, et al.
Publicado: (2016)

Spontaneous rectal sheath bleed while on DOAC anticoagulation
por: de Courcy, Louis, et al.
Publicado: (2023)

Real-world effectiveness and safety of oral anticoagulation strategies in atrial fibrillation: a cohort study based on a German claims dataset
por: Mueller, Sabrina, et al.
Publicado: (2018)

Relation of the ‘Atrial Fibrillation Better Care (ABC) Pathway’ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists
por: Roldán, Vanessa, et al.
Publicado: (2022)

Which Renal Function Equation Should Be Used for Prescribing DOACs in Patients With Atrial Fibrillation?
por: Wang, Yilong, et al.
Publicado: (2022)

Correction to: Anticoagulant Treatment Adherence and Persistence in German Patients with Atrial Fibrillation
por: Patti, Giuseppe, et al.
Publicado: (2023)

Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation
por: Ding, Wern Yew, et al.
Publicado: (2022)

Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation
por: Saliba, Walid
Publicado: (2015)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease
por: Moon, Inki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u06ndff32dvn74mfd9boh8vdpf